SCH 430765 and SCH 500496 are potent and selective antagonists of the NPY5 receptor. NPY5 receptor antagonists have the potential for the treatment of obesity. [S-35]SCH 500946 was prepared for a competition binding assay which led to the identification of SCH 430765. Three distinct isotopically labelled forms of SCH 430765 were synthesized. [H-3]SCH 430765 was prepared for a preliminary absorption, distribution, metabolism and excretion data evaluation of the compound and [C-14]SCH 430765 for more definitive absorption, distribution, metabolism and excretion data work. In addition, [C-13(2),H-2(4)]SCH 430765 was prepared as an internal standard for a LC-MS bioanalytical method. The paper discusses the synthesis of 3 isotopically labelled forms of SCH 430765 and [S-35]SCH 500946.
Synthesis of H-3, C-13(2), H-2(4) C-14-SCH 430765 and S-35-SCH 500946, potent and selective inhibitors of the NPY5 receptor
Hesk, D., Koharski, D., McNamara, P., Royster, P., Saluja, S., Truong, V., & Voronin, K. (2018). Synthesis of H-3, C-13(2), H-2(4) C-14-SCH 430765 and S-35-SCH 500946, potent and selective inhibitors of the NPY5 receptor. Journal of Labelled Compounds and Radiopharmaceuticals, 61(7), 533-539. https://doi.org/10.1002/jlcr.3617
To contact an RTI author, request a report, or for additional information about publications by our experts, send us your request.
Multifaceted risk for non-suicidal self-injury only versus suicide attempt in a population-based cohort of adults
Community overdose surveillance
Epigenetic biomarkers for smoking cessation